Human SR-AI/MSR Alexa Fluor™ Plus 680-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB2708AFP680
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Specificity
Clonality
Host
Isotype
Applications
CyTOF-reported
Flow Cytometry
Western Blot
Background: SR-AI/MSR
The type I class A macrophage scavenger receptor (SR-AI; also MSR-AI) is a 70-80 kDa protein that belongs to the scavenger receptor superfamily (1‑3). Receptors of this family contain characteristic extracellular domains and bind to a series of generally unrelated, but negatively-charged/polyanionic ligands (1, 3). Human SR-AI is a type II transmembrane glycoprotein that is 451 amino acids (aa) in length. It contains a 50 aa cytoplasmic tail, a 26 aa transmembrane segment and a 375 aa extracellular region (4, 5). The extracellular region contains four definitive domains, with a membrane proximal spacer of 33 aa, an alpha-helical coiled-coil domain of 163 aa, a collagen-like domain of 69 aa, and a cysteine-rich C-terminus of 110 aa (4, 6). The cysteine-rich domain (CRD) forms three intrachain disulfide bonds (7). The functional form of the molecule is a 220‑230 kDa membrane-associated trimer that, in human, apparently has two disulfide bonded chains and a third noncovalently associated subunit (8, 9). Human extracellular region is 73% and 72% aa identical to bovine and mouse SR-AI extracellular region, respectively. The human gene for SR-A gives rise to three isoforms; the I isoform of 451 aa, the II isoform of 358 aa, and the III isoform of 388 aa (4, 5, 10). All are identical through the first 344 aa which includes the cytoplasmic tail through the collagenous domain. Isoform II (SR-AII) shows a severe truncation of the CRD, but is expressed on the cell surface. Isoform III (SR-AIII) has a modest truncation of the CRD, and cannot be expressed on the cell surface. However, relative to SR-AI, SR-AII is known to show differential sensitivity to LPS and receptor binding to gram‑negative bacteria (9, 11), while SR-AIII is known to be a dominant-negative isoform (10). SR-AIII may achieve this by either heterotrimerizing with SR-AI, or simply eliminating the production of SR-AI mRNA.
References
- Platt, N. and S. Gordon (2001) J. Clin. Invest. 108:649.
- Linton, M.F. and S. Fazio (2001) Curr. Opin. Lipidol. 12:489.
- Platt, N. and S. Gordon (1998) Chem. Biol. 5:R193.
- Matsumoto, A. et al. (1990) Proc. Natl. Acad. Sci. USA 87:9133.
- Emi, M. et al. (1993) J. Biol. Chem. 268:2120.
- Naito, M. et al. (1992) Am. J. Pathol. 141:591.
- Resnick, D. et al. (1996) J. Biol. Chem. 271:26924.
- Ashkenas, J. et al. (1993) J. Lipid Res. 34:983.
- Penman, M. et al. (1991) J. Biol. Chem. 266:23985.
- Gough, P.J. et al. (1998) J. Lipid Res. 39:531.
- Peiser, L. et al. (2000) Inf. Immun. 68:1953.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional SR-AI/MSR Products
Product Specific Notices
This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.
For research use only